S'abonner

Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia - 25/08/11

Doi : 10.1016/j.amjmed.2003.10.027 
Naoki Kotani, MD, PhD a, b, , Ryoko Kudo c, Yutaka Sakurai, MD, PhD d, Daisuke Sawamura, MD, PhD e, Daniel I Sessler, MD a, f, Hiroshi Okada, MD, PhD g, Hiroto Nakayama, MD, PhD g, Toshifumi Yamagata h, Minoru Yasujima, MD, PhD c, Akitomo Matsuki, MD, PhD c
a Outcomes Research Group (NK, DIS), Yamagata, Japan 
b Department of Anesthesiology (NK), Yamagata University, Yamagata, Japan 
c Departments of Anesthesiology and Laboratory Medicine (RK, MY, AM), University of Hirosaki, Hirosaki, Japan 
d Department of Hygiene (YS), National Defense Medical College, Tokorozawa, Japan 
e Department of Dermatology (DS), Hokkaido University, Sapporo, Japan 
f Department of Anesthesiology (DIS), University of Louisville, Louisville, Kentucky, USA 
g Department of Anesthesiology (HO, HN), Iwate Medical University, Morioka, Japan 
h Tohoku Chemical Co. Ltd (TY), Hirosaki, Japan 

*Requests for reprints should be addressed to Naoki Kotani, MD, PhD, Department of Anesthesiology, Yamagata University School of Medicine, Yamagata 990-9585, Japan

Abstract

Purpose

Other than age, the risk factors for postherpetic neuralgia are not well established. We studied whether the concentration of interleukin 8 in the cerebrospinal fluid is associated with the risk of postherpetic neuralgia.

Methods

We enrolled 170 patients more than 50 years old who had a typical painful and nontrigeminal herpetic rash. Patients were treated with acyclovir; no corticosteroids were given. Cerebrospinal fluid was taken for analysis of interleukin 8 during and at full crusting of the herpetic rash. Age, sex, comorbid conditions, prodromal pain, localization and severity of herpetic rash, number of skin lesions, and degree of pain were recorded. We used multivariate logistic regression modeling to identify significant predictive factors. Receiver operating characteristic (ROC) curves were evaluated to determine the contribution of each factor.

Results

Six months after healing, 31 patients (18%) had postherpetic neuralgia; 27 patients still had it after 1 year. Only three variables—age (odds ratio [OR] = 2.7 per 10-year increase; 95% confidence interval [CI]: 1.2 to 6.2), acute pain (OR = 1.8 per unit increase in visual analog scale; 95% CI: 1.2 to 2.8), and interleukin 8 concentration in the cerebrospinal fluid at full crusting of the herpetic rash (OR = 1.6 per 20-μg/L increase; 95% CI: 1.3 to 2.0)—were significant predictors of postherpetic neuralgia at 1 year. Interleukin 8 concentration also had the highest area under the ROC curve at these evaluation points (P <0.001).

Conclusion

Our results suggest that interleukin 8 concentration in the cerebrospinal fluid at full crusting of herpetic rash may be useful for identifying patients who are likely to develop intractable postherpetic neuralgia.

Le texte complet de cet article est disponible en PDF.

Plan


 This work was supported by Grants-in-aid for Scientific Research B2-30205415 and C2-14571415 from the Ministry of Education and Science, Tokyo, Japan; Grant-in-aid for Cancer Research No. 11-1 from the Ministry of Health, Labor, and Welfare, Tokyo, Japan; grants GM58273 and GM061655 from the National Institutes of Health, Bethesda, Maryland; the Joseph Drown Foundation, Los Angeles, California; and the Commonwealth of Kentucky Research Challenge Trust Fund, Louisville, Kentucky.


© 2004  Excerpta Medica Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 116 - N° 5

P. 318-324 - mars 2004 Retour au numéro
Article précédent Article précédent
  • Regional cerebral hypoperfusion in patients with celiac disease
  • Giovanni Addolorato, Daniela Di Giuda, Giuseppe De Rossi, Venanzio Valenza, Marco Domenicali, Fabio Caputo, Antonio Gasbarrini, Esmeralda Capristo, Giovanni Gasbarrini
| Article suivant Article suivant
  • Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity
  • Donald D Sin, Kamran Golmohammadi, Philip Jacobs

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.